



AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application.

1. (Currently amended) A compound of formula (I)



wherein A represents A1



- R is unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, heteroaryl, heteroaryl-(C₁-C₁₀-alkyl)-, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)-, C₃-C₁₀-cycloalkyl, polycycloalkyl, C₂-C₁₀-alkenyl or C₂-C₁₀-alkinyl,

where the substituents are chosen from halogen, -CN, C₁-C₁₀-alkyl, -NO₂, -OR1, -C(O)OR1, -O-C(O)R1, -NR1R2, -NHC(O)R1, -C(O)NR1R2, -SR1, -S(O)R1, -SO₂R1, -NHSO₂R1, -SO₂NR1R2, -C(S)NR1R2, -NHC(S)R1, -O-SO₂R1, -SO₂-O-R1, oxo, -C(O)R1, -C(NH)NH₂, heterocyclyl, C₃-C₁₀-cycloalkyl, aryl-(C₁-C₆-alkyl)-, aryl, heteroaryl, trifluoromethyl, trifluoromethylsulfanyl and trifluoromethoxy,

and the substituents aryl, heterocyclyl and heteroaryl may further be at least monosubstituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen, trifluoromethyl, trifluoromethoxy or OH;

Ar is unsubstituted or at least monosubstituted aryl or heteroaryl; is unsubstituted or at least monosubstituted phenyl, pyridinyl, pyrimidinyl, pyrazolyl, thiophenyl, isoxazolyl, benzof[thiophenyl, benzodioxolyl or thiazolo[3,2-b][1,2,4]-thiazolyl,

where the substituents are chosen from halogen, NO₂, C₁-C₁₀-alkyl, -OH, -C(O)OR₁, -O-C(O)R₁, -NR₁R₂, -NHC(O)R₁, -C(O)NR₁R₂, -NHC(S)R₁, -C(S)NR₁R₂, -SR₁, -S(O)R₁, -SO₂R₁, -NHSO₂R₁, -SO₂NR₁R₂, -O-SO₂R₁, -SO₂-O-R₁, aryl, heteroaryl, aryl-(C₁-C₆-alkyl)-, formyl, trifluoromethyl and trifluoromethoxy,

and the substituents aryl and heteroaryl may further be at least monosubstituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen, trifluoromethyl, trifluoromethoxy or OH;

R₁ and R₂, independently from each other, are

hydrogen;

unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, C₃-C₁₀-cycloalkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)- or heteroaryl, where the substituents are chosen from halogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, CN, NO₂, NH₂, (C₁-C₆-alkyl)amino-, di(C₁-C₆-alkyl)amino-, OH, COOH, -COO-(C₁-C₆-alkyl), -CONH₂, formyl, trifluoromethyl and trifluoromethoxy;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O and S;

aryl is phenyl, indanyl, indenyl or naphthyl;

heterocyclyl is a 5 to 10-membered, aliphatic, mono- or bicyclic heterocycle containing one or more heteroatoms chosen from N, O and S;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof;

with the proviso that A is not -C(O)NH(C₁-C₆-alkyl), when Ar is phenyl which is at least monosubstituted with heterocyclyl or heteroaryl containing nitrogen;

~~wherein when Ar is a 9-membered bicyclic heterocycle containing one or more heteroatoms selected from N, O and S, Ar is unsubstituted.~~

2. (Previously presented) The compound according to claim 1, wherein in the formula (I)

A is A₁;

R is unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, heteroaryl, heteroaryl-(C₁-C₁₀-alkyl)-, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)-, C₃-C₁₀-cycloalkyl, polycycloalkyl, C₂-C₁₀-alkenyl or C₂-C₁₀-alkinyl,

where the substituents are chosen from halogen, -CN, C₁-C₁₀-alkyl, -NO₂, -OR₁, -C(O)OR₁, -O-C(O)R₁, -NR₁R₂, -NHC(O)R₁, -C(O)NR₁R₂, -SR₁, -S(O)R₁, -SO₂R₁, -NHSO₂R₁, -SO₂NR₁R₂, -C(S)NR₁R₂, -NHC(S)R₁, -O-SO₂R₁, -SO₂-O-R₁, oxo, -C(O)R₁, -C(NH)NH₂, heterocyclyl, C₃-C₁₀-cycloalkyl, aryl-(C₁-C₆-alkyl)-, aryl, heteroaryl, trifluoromethyl, trifluoromethylsulfanyl and trifluoromethoxy,

and the substituents aryl, heterocyclyl and heteroaryl may further be at least monosubstituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen, trifluoromethyl, trifluoromethoxy or OH;

R1 and R2, independently from each other, are

hydrogen;

unsubstituted or at least monosubstituted C₁-C₁₀-alkyl,
C₃-C₁₀-cycloalkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, C₂-C₁₀-alkenyl,
C₂-C₁₀-alkinyl, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)- or heteroaryl,
where the substituents are chosen from halogen, C₁-C₆-alkyl,
C₁-C₆-alkoxy, CN, NO₂, NH₂, (C₁-C₆-alkyl)amino-,
di(C₁-C₆-alkyl)amino-, OH, COOH, -COO-(C₁-C₆-alkyl), -CONH₂, formyl,
trifluoromethyl and trifluoromethoxy;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle
containing one or more heteroatoms chosen from N, O and S;

aryl is phenyl, indanyl, indenyl or naphthyl;

heterocyclyl is a 5 to 10-membered, aliphatic, mono- or bicyclic heterocycle
containing one or more heteroatoms chosen from N, O and S;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the
tautomers or the physiologically acceptable salts thereof.

3. (Previously presented) The compound according to claim 1, wherein in
the formula (I)

R is unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, aryl,
aryl-(C₁-C₁₀-alkyl)-, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)-,
C₃-C₁₀-cycloalkyl, heteroaryl or heteroaryl-(C₁-C₁₀-alkyl)-,

where the substituents are chosen from halogen, -CN, C₁-C₁₀-alkyl,
-NO₂, -OR1, -C(O)OR1, -O-C(O)R1, -NR1R2, -NHC(O)R1,
-C(O)NR1R2, -SR1, -S(O)R1, -SO₂R1, -NHSO₂R1, -SO₂NR1R2,

-C(S)NR₁R₂, -NHC(S)R₁, -O-SO₂R₁, -SO₂-O-R₁, oxo, -C(O)R₁,
-C(NH)NH₂, heterocyclyl, C₃-C₁₀-cycloalkyl, aryl-(C₁-C₆-alkyl)-, aryl,
heteroaryl, trifluoromethyl, trifluoromethylsulfanyl and trifluoromethoxy,

and the substituents aryl, heterocyclyl and heteroaryl may further be at
least monosubstituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen,
trifluoromethyl, trifluoroethoxy or OH;

R₁ and R₂, independently from each other, are

hydrogen;

unsubstituted or at least monosubstituted C₁-C₁₀-alkyl,
C₃-C₁₀-cycloalkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, C₂-C₁₀-alkenyl,
C₂-C₁₀-alkinyl, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)- or heteroaryl,
where the substituents are chosen from halogen, C₁-C₆-alkyl,
C₁-C₆-alkoxy, CN, NO₂, NH₂, (C₁-C₆-alkyl)amino-,
di(C₁-C₆-alkyl)amino-, OH, COOH, -COO-(C₁-C₆-alkyl), -CONH₂, formyl,
trifluoromethyl and trifluoromethoxy;

heteroaryl is a 5 to 10-membered, aromatic, mono- or bicyclic heterocycle
containing one or more heteroatoms chosen from N, O and S;

aryl is phenyl, indanyl, indenyl or naphthyl;

heterocyclyl is a 5 to 10-membered, aliphatic, mono- or bicyclic heterocycle,
containing one or more heteroatoms chosen from N, O and S;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the
tautomers or the physiologically acceptable salts thereof.

4. (Currently amended) The compound according to claim 1, wherein in the
formula (I)

Ar — is unsubstituted or at least monosubstituted phenyl, pyridinyl, pyrimidinyl, pyrazolyl, thiophenyl, isoxazolyl, benzo[b]thiophenyl, benzodioxolyl or thiazolo[3,2-b][1,2,4]thiazolyl,

where the substituents are chosen from halogen, NO₂, C₁-C₄₀-alkyl, OH, C(O)OR₁, O-C(O)R₁, NR₁R₂, NHC(O)R₁, C(O)NR₁R₂, NHC(S)R₁, C(S)NR₁R₂, SR₁, S(O)R₁, SO₂R₁, NHSO₂R₁, SO₂NR₁R₂, O-SO₂R₁, SO₂-O-R₁, aryl, heteroaryl, aryl-(C₁-C₆-alkyl), formyl, trifluoromethyl and trifluoromethoxy,

and the substituents aryl and heteroaryl may further be at least monosubstituted with C₁-C₆-alkyl, C₁-C₆-alkoxy, halogen, trifluoromethyl, trifluoromethoxy or OH;

R₁ and R₂, independently from each other, are

hydrogen;

unsubstituted or at least monosubstituted C₁-C₁₀-alkyl, C₃-C₁₀-cycloalkyl, aryl, aryl-(C₁-C₁₀-alkyl)-, C₂-C₁₀-alkenyl, C₂-C₁₀-alkinyl, heterocyclyl, heterocyclyl-(C₁-C₁₀-alkyl)- or heteroaryl, where the substituents are chosen from halogen, C₁-C₆-alkyl, C₁-C₆-alkoxy, CN, NO₂, NH₂, (C₁-C₆-alkyl) amino-, di(C₁-C₆-alkyl)amino-, OH, COOH, -COO-(C₁-C₆-alkyl), -CONH₂, formyl, trifluoromethyl and trifluoromethoxy;

heteroaryl is a 5 to 10-membered aromatic, mono- or bicyclic heterocycle, containing one or more heteroatoms chosen from N, O and S;

aryl is phenyl, indanyl, indenyl or naphthyl;

heterocyclyl is a 5 to 10-membered aliphatic, mono- or bicyclic heterocycle, containing one or more heteroatoms chosen from N, O and S;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.

5. (Previously presented) The compound according to claim 1, wherein in the formula (I)

A is A1;

R is unsubstituted or at least monosubstituted aryl-(C₁-C₆-alkyl)-heteroaryl-(C₁-C₆-alkyl)- or heterocyclyl-(C₁-C₆-alkyl)-,

where the substituents are chosen from halogen, C₁-C₆-alkyl, -OH, -O-aryl, C₁-C₆-alkoxy, -O-(C₁-C₆-alkyl)-N(C₁-C₆-alkyl)₂, -C(O)OH, -C(O)O-(C₁-C₆-alkyl), -NH₂, -N(C₁-C₆-alkyl)₂, -NH(C₁-C₆-alkyl), -NH(C₁-C₁₀-cycloalkyl), -C(O)NH₂, -C(O)NH-heteroaryl, -C(O)NH-(C₁-C₆-alkyl), -SO₂(C₁-C₆-alkyl), -SO₂NH₂, -C(O)-heterocyclyl, -C(NH)NH₂, heterocyclyl, aryl-(C₁-C₆-alkyl)-, aryl, trifluoromethyl, and trifluoromethoxy,

and the substituents aryl, heterocyclyl and heteroaryl may further be at least monosubstituted with C₁-C₃-alkyl, C₁-C₃-alkoxy, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy or OH;

heteroaryl is imidazolyl, thiophenyl, furanyl, isoxazolyl, pyridinyl, pyrimidinyl, benzoimidazolyl, indolyl or benzodioxolyl;

aryl is phenyl or naphthyl;

heterocyclyl is morpholinyl, piperazinyl or piperidinyl;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.

6. (Previously presented) The compound according to claim 1, wherein in the formula (I)

A is A1;

Ar is unsubstituted or at least monosubstituted phenyl, pyridin-4-yl or pyrimidin-4-yl,

where the substituents are chosen from halogen, C₁-C₆-alkyl, -OH, -C(O)OH, -C(O)O-(C₁-C₆-alkyl), -NH₂, -N(C₁-C₆-alkyl)₂, -NH(C₁-C₆-alkyl), -NH(C₁-C₁₀-cycloalkyl), -NH(heterocyclyl-(C₁-C₆-alkyl-)), -NH(aryl-(C₁-C₆-alkyl-)), -C(O)NH₂, -C(O)NH-(C₁-C₆-alkyl), aryl, and heteroaryl,

and the substituents aryl, heterocyclyl and heteroaryl may further be at least monosubstituted with C₁-C₃-alkyl, C₁-C₃-alkoxy, fluorine, chlorine, bromine, trifluoromethyl, trifluoromethoxy or OH;

heteroaryl is pyridinyl or pyrimidinyl;

aryl is phenyl or naphthyl;

heterocyclyl is morpholinyl, piperazinyl or piperidinyl;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.

7. (Previously presented) The compound according to claim 1, wherein in the formula (I)

A is A1;

R is unsubstituted or at least monosubstituted benzyl, phenylethyl-, phenylpropyl-, piperazinylpropyl-, pyridinylmethyl-, pyridinylethyl- or pyridinylpropyl-,

where the substituents are chosen from chlorine, bromine, fluorine, trifluoromethyl, methyl, ethyl, propyl, methoxycarbonyl and carboxy;

Ar is unsubstituted or at least monosubstituted pyridin-4-yl, pyrimidin-4-yl or phenyl,

where the substituents are chosen from methylamino-, ethylamino-, propylamino-, butylamino-, hydroxy, methyl, ethyl, propyl, (phenylethyl)amino-, benzylamino-, and (morpholinylethyl)amino-;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.

8. (Currently amended) The compound according to claim 1 chosen from

6-(2-butylamino-pyrimidin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide,

~~6-(4-hydroxy-3-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide,~~

6-(4-hydroxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide,

6-(2-ethylamino-pyrimidin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

6-(3-chloro-4-hydroxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

6-(2-butylamino-pyrimidin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (pyridin-3-yl-methyl)-amide,

6-(3-fluoro-4-hydroxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

6-[2-(2-morpholin-4-yl-ethylamino)-pyrimidin-4-yl]-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

N-(3,4-dichlorobenzyl)-3-oxo-6-pyridin-4-yl-2,3-dihydropyridazin-4-carboxamide,

3-oxo-6-pyridin-4-yl-2,3-dihydro-pyridazine-4-carboxylic acid [2-(2-chloro-phenyl)-ethyl]-amide,

6-(2-methylamino-pyridin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzyl amide,

R-3-oxo-6-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide,

6-(2-butylamino-pyrimidin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid [3-(4-methyl-piperazin-1-yl)-propyl]-amide,

4-[[3-oxo-6-pyridin-4-yl-2,3-dihydro-pyridazine-4-carbonyl]-amino]-methyl]-benzoic acid methyl ester,

6-(2-methylamino-pyrimidin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide,

6-(2-methylamino-pyrimidin-4-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

6-(4-hydroxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide,

3-oxo-6-pyridin-4-yl-2,3-dihydro-pyridazine-4-carboxylic acid 4-bromo-benzylamide,

N-(2,4-dichlorobenzyl)-3-oxo-6-pyridin-4-yl-2,3-dihydropyridazine-4-carboxamide,

3-oxo-6-pyridin-4-yl-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-2-fluoro-benzylamide, and

N-(4-chlorobenzyl)-3-oxo-6-pyridin-4-yl-2,3-dihydropyridazine-4-carboxamide;

or the racemates, enantiomers, diastereoisomers and mixtures thereof, the tautomers or the physiologically acceptable salts thereof.


9.-25. (Cancelled).

26. (Original) A pharmaceutical preparation comprising an effective dose of at least one compound or a physiologically acceptable salt thereof as defined in claim 1 and a physiologically acceptable carrier.

27. (Original) The pharmaceutical preparation according to claim 26, which pharmaceutical preparation is in the form of a pill, tablet, lozenge, coated tablet, granule, capsule, hard or soft gelatin capsule, aqueous solution, alcoholic solution, oily solution, syrup, emulsion suspension, pastille, suppository, solution for injection or infusion, ointment, tincture, cream, lotion, powder, spray, transdermal therapeutic systems, nasal spray, aerosol mixture, microcapsule, implant, rod or plaster.

28. (Previously presented) A method for the synthesis of a compound of formula (I) according to claim 1, wherein

a) a compound of formula (IV)



wherein Y1 is halogen, $B(OH)_2$ or $Sn(C_1-C_{10}\text{-alkyl})$ and


Y2 is H or a protecting group,

is converted with Ar-Z in presence of a palladium complex, where Z is $B(OH)_2$,

$B(C_1-C_{10}\text{-alkoxy})_2$, $Sn(C_1-C_{10}\text{-alkyl})_3$, $Zn(C_1-C_{10}\text{-alkyl})$ or halogen,

or

b) in formula (I) when A is A1, a compound of formula (II)



wherein X is -OH, $C_1-C_{10}\text{-alkoxy}$, chlorine or $-O-C(O)O-(C_1-C_{10}\text{-alkyl})$,

is converted with RNH_2 .

29. (Previously presented) A compound, chosen from

6-(4-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide;

6-(4-hydroxy-3-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide;

6-(4-hydroxy-3-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid (3-pyridin-3-yl-propyl)-amide;

6-(4-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide;

4-[5-(4-chloro-benzylcarbamoyl)-6-oxo-1,6-dihydro-pyridazin-3-yl]-3-methoxy-thiophene-2-carboxylic acid;

6-(5-carbamoyl-4-methoxy-thiophen-3-yl)-3-oxo-2,3-dihydro-pyridazine-4-carboxylic acid 4-chloro-benzylamide; and

4-({[6-(4-hydroxy-3-methoxy-phenyl)-3-oxo-2,3-dihydro-pyridazine-4-carbonyl]-amino}-methyl)-benzoic acid.

30. (Cancelled).

31. (New) A pharmaceutical preparation comprising an effective dose of at least one compound or a physiologically acceptable salt thereof as defined in claim 29 and a physiologically acceptable carrier.

32. (New) The pharmaceutical preparation according to claim 31, which pharmaceutical preparation is in the form of a pill, tablet, lozenge, coated tablet, granule, capsule, hard or soft gelatin capsule, aqueous solution, alcoholic solution, oily solution, syrup, emulsion suspension, pastille, suppository, solution for injection or infusion, ointment, tincture, cream, lotion, powder, spray, transdermal therapeutic systems, nasal spray, aerosol mixture, microcapsule, implant, rod or plaster.